{"filing":{"accession_number":"0001575872-26-000444","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-06-26","report_date":null,"primary_document":"rdy0911_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000444/rdy0911_6k.htm"},"events":[{"id":14159,"run_id":12596,"accession_number":"0001575872-26-000444","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Dr. Reddy's discloses completion of a USFDA Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad, with issuance of a Form 483 containing seven observations. This is a regulatory inspection outcome at a material manufacturing facility that could affect the company's ability to obtain or maintain FDA approval for biologics products. While not a discrete event like a product approval or facility closure, it is a material regulatory development requiring disclosure under SEBI Regulation 30 and represents an operational/regulatory matter that does not fit the specific event categories (not a restatement, going concern, material impairment, or litigation).","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-06-26","form":"6-K","submitted_at":null,"items":[{"id":11506,"accession_number":"0001575872-26-000444","item_number":"EX-99.1","item_title":"rdy0911_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's discloses completion of a USFDA Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad, with issuance of a Form 483 containing seven observations. This is a regulatory inspection outcome at a material manufacturing facility that could affect the company's ability to obtain or maintain FDA approval for biologics products. While not a discrete event like a product approval or facility closure, it is a material regulatory development requiring disclosure under SEBI Regulation 30 and represents an operational/regulatory matter that does not fit the specific event categories (not a restatement, going concern, material impairment, or litigation).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T15:59:38.317339+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11506,"accession_number":"0001575872-26-000444","item_number":"EX-99.1","item_title":"rdy0911_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's discloses completion of a USFDA Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad, with issuance of a Form 483 containing seven observations. This is a regulatory inspection outcome at a material manufacturing facility that could affect the company's ability to obtain or maintain FDA approval for biologics products. While not a discrete event like a product approval or facility closure, it is a material regulatory development requiring disclosure under SEBI Regulation 30 and represents an operational/regulatory matter that does not fit the specific event categories (not a restatement, going concern, material impairment, or litigation).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T15:59:38.317339+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-06-26"}]}